Boies Schiller Flexner adds three-strong litigation team
24 June 2025   Trio have worked together for several years at different firms, bringing decades of experience in medical devices, robotics, and life sciences.

Latest Features

Europe
Despite efforts to harmonise, the Unified Patent Court’s local divisions and Court of Appeal have signalled a divergence over implementing the European Patent Convention—but does it matter? Chris Moore and Hsu Min Chung of HGF report.
Europe
Two years since the UPC opened its doors, various developments might influence the UK government to reassess its position, write Amanda Ebbutt and Paul England of Taylor Wessing.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
Africa
Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International.
Europe
Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date.
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.
Europe
Supplementary Protection Certificate rules interpreted in different ways have left the EU’s generic and biosimilar industries hungry for clarity, explains Jiri Slavik of Adalvo.
Unified Patent Court
The UPC Court of Appeal’s approach to delivering a preliminary injunction in a glucose sensor dispute has far-reaching effects, as Wouter Pors of Bird & Bird explains.
All features


More News

19 June 2025   The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.
19 June 2025   Former in-house counsel at major pharma companies brings expertise in IP strategy, regulatory compliance, and business development across pharma and biotech.
17 June 2025   Court affirms infringement of patent covering gene expression technology | Curio Bioscience cannot sell related products in three EU countries | Decision is “further testament to 10x Genomic’s strategic use of IP”, 10x counsel tells LSIPR.
17 June 2025   Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation over whether it was a mistake or calculated move in a country known for strict drug price controls.
17 June 2025   Ex-co-head of life sciences at previous firm brings expertise in multi-jurisdictional patent disputes involving supplementary protection certificates and second medical use claims.
13 June 2025   Government unveils £8M OpenBind consortium to lead in AI drug discovery | Project to build world’s largest drug–protein dataset | Backed by new Sovereign AI Unit, Consortium will be based at national synchrotron facility in Oxfordshire.
12 June 2025   Unified Patent Court announces new case management system this summer | Release will be in two phases, with first phase focusing on opt-out functionalities and representatives’ registration.
More news